Mechthild Budde

Learn More
BACKGROUND This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with placebo as intravenous (i.v.) therapy in metastatic bone disease due to breast cancer. PATIENTS AND METHODS A total of 466 patients were randomised to receive placebo (n = 158), or 2 mg (n = 154) or 6 mg (n = 154) ibandronate every 3-4 weeks for up to(More)
Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life. It was the aim of the present study to assess changes in quality of life and bone pain due to intravenous (i.v.) ibandronate, a potent third-generation bisphosphonate. In a phase III randomised,(More)
This large prospectively conducted observational cohort study examined the risk of lymphoma and other malignancies with mycophenolate mofetil (MMF) in de novo renal transplant recipients. A total of 6751 patients receiving MMF, and an equal number of matched controls receiving non-MMF-based immunosuppression, were identified from two large registries (Organ(More)
BACKGROUND Minimising the concentration of active ingredient in rodenticide bait is desirable economically and for the protection of the agroecosystem. This study aimed to identify a zinc phosphide concentration that balances palatability and efficacy for common vole (Microtus arvalis Pall.) management and to compare the attractiveness of two bait carriers.(More)
735 Background: Ibandronate is a highly-potent aminobisphosphonate for the prevention of skeletal events from metastatic bone disease. A 3-month trial has assessed the safety and effects on bone turnover of a single rapid infusion of i.v. ibandronate, followed by daily oral dosing. This abstract reports the safety results. METHODS In a multicenter,(More)
Retrospective analysis of 97 children aged 3 months to 15 years presented for liver transplantation in our clinic indicates that children with extrahepatic biliary atresia (BA) show a cumulative survival of only 27% after 2.5 years of observation without transplantation. Children with cirrhosis of the liver of other origin (C) have an even worse cumulative(More)
In study COSS-80 113 evaluable patients (pts) received neoadjuvant preoperative chemotherapy (prop CT) with highdose methotrexate (HD-MTX), doxorubicine (DOX) and either cisplatinum (DDP) or the triple drug combination bleomycine&cyclophosphamide&dactinomycine (BCD). Half of the pts received in addition fibroblast interferon following surgery in wk 12. The(More)
  • 1